got separated looks like lol.
Word Mark RESCUJECT
Goods and Services IC 005. US 006 018 044 046 051 052. G & S: Injectable pharmaceuticals for treatment of anaphylactic reactions
Mark Drawing Code (4) STANDARD CHARACTER MARK
Serial Number 86916799
Filing Date February 23, 2016
Current Basis 1B
Original Filing Basis 1B
Published for Opposition May 10, 2016
Owner (APPLICANT) Teva Pharmaceuticals USA, Inc. CORPORATION PENNSYLVANIA 1090 Horsham Road North Wales PENNSYLVANIA 19454
Type of Mark TRADEMARK
Live/Dead Indicator LIVE
meant to say, Nobody would have a clue IF it weren't for you Loko! Thanks for all your DD!
Excellent ! Great dig. Nobody would have a clue. This company (or our VP PR man) is probably helping the shorts to sell short, then cover so easily; nothing else makes any sense. For RESCUJECT the 1st reference says a lot as it speaks of "allergy" treatment: "Word Mark RESCUJECT
Goods and Services IC 044. US 100 101. G & S: Providing health information regarding allergies and the treatment thereof via email, website, video, text messages, telephone, and social media."
I like and follow your posts but do not always comment. Did you vote your shares by proxy (as I did) or are you going to ASM in person to boo Jack from the audience lol?
I, as you, wish I never bought into this company--- nothing ever pans out well for them in a timely manner (except their salaries, bonuses, stock awards and severance pay).
I'd be very happy with a $100,000 profit starting in Q2 2017. That's how much I've lowered my expectations for Otrexup.
Consistent with its pay for performance philosophy, the Compensation Committee considered the impact of our corporate performance during 2015 in determining named executive officer compensation for 2015, as well as each named executive officer’s individual performance, macroeconomic conditions generally, and data from peer group companies. In addition, the Compensation Committee considered the significant support from our stockholders with respect to the compensation of our named executive officers from the prior year, with approximately 96% of stockholder votes cast in favor of our Say on Pay resolution approved at our May 2015 Annual Meeting of Stockholders.
I VOTED NO to Proposal #2. Also NO to Proposals #4 and #5.
EPI fooled everyone ... there were naysayers but in truth they just got lucky with the surprise delay. I hope you get your $$ back doubled.
It don't think a single share has been sold since May 5 by anyone that reads this board. Certainly not due to his #$%$ comments. Stockvader is only communicating with Stockvader here, a kind of mental masturbation commonly practiced by novices living in their parents basements.
Can anyone confirm if the Pre-filled syringe referenced has indeed been approved?
At March 31, 2016, cash and investments totaled approximately $42.1 million compared to approximately $47.9 million at December 31, 2015.
Currently a 6M quarterly burn rate. Can we go on this way 4 more QTs before it becomes a more serious problem? Hoping for a QST partnership soon and an EPI resolution.
In this case it sure looks like most of the high volume came from buying to cover, especially since the stock price did not hold the new level above $1. Bullish but not a classic sign of accumulation I don't think.
The chart clearly shows unusually large volume on the up days (the 7-8 days when ATRS traded above $1) and very significantly lower volume on the down days. What does a price/volume relationship like this accompanied by a simultaneously occurring record 14 day drop in Short Interest usually portend?